Cargando…

Efficacy and safety of a Chinese herbal formula Maxing Ganshi Decoction in children with community-acquired pneumonia: A randomized, double-blind, placebo-controlled, multicenter trial

Background: As one of the most commonly used Chinese medicine formula in the manage of respiratory diseases, Maxing Ganshi Decoction (MGD) has been demonstrated to improve the clinical symptoms of pneumonia. To evaluate the efficacy and safety of MGD in treating children with community-acquired pneu...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Yujiao, Shi, Changren, Han, Yaowei, Li, Xinmin, Dong, Lijing, Li, Yan, Chen, Hui, Wang, Yushui, Li, Jinsong, Liu, Geli, Ma, Rong, Lian, Fengmei, Tong, Xiaolin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9479123/
https://www.ncbi.nlm.nih.gov/pubmed/36120338
http://dx.doi.org/10.3389/fphar.2022.948831
_version_ 1784790720325877760
author Zheng, Yujiao
Shi, Changren
Han, Yaowei
Li, Xinmin
Dong, Lijing
Li, Yan
Chen, Hui
Wang, Yushui
Li, Jinsong
Liu, Geli
Ma, Rong
Lian, Fengmei
Tong, Xiaolin
author_facet Zheng, Yujiao
Shi, Changren
Han, Yaowei
Li, Xinmin
Dong, Lijing
Li, Yan
Chen, Hui
Wang, Yushui
Li, Jinsong
Liu, Geli
Ma, Rong
Lian, Fengmei
Tong, Xiaolin
author_sort Zheng, Yujiao
collection PubMed
description Background: As one of the most commonly used Chinese medicine formula in the manage of respiratory diseases, Maxing Ganshi Decoction (MGD) has been demonstrated to improve the clinical symptoms of pneumonia. To evaluate the efficacy and safety of MGD in treating children with community-acquired pneumonia (CAP), we conducted the clinical trial. Methods: A randomized, double-blind, placebo-controlled, multicenter trial was conducted in 3 study sites in Tianjin, China. MDG or placebo were randomly given to patients aged 3–6 years with onset of CAP within 48 h. Changes in disease efficacy during the study period (which was measured as recovery, significant effect, improvement and no effect) was evaluated as the primary outcome. Time from enrollment to fever resolution was assessed as the secondary outcome. The adverse event was analyzed as safety evaluation. Results: A total of 71 patients (36 in MGD and 35 in placebo) were randomized and completed the whole study. The patient demographics and other characteristics at baseline were similar between the 2 groups (p > 0.05). After 10 days of intervention, the proportion of recovered and significant effective patients was increased significantly in the MGD group (34.85% [95% CI, 12.44%–57.26%]; p < 0.05) compared with the control group. Besides, the symptom score of the MGD group was lowered significantly (p < 0.001). The estimated time to fever resolution in the MGD group was also reduced compared with the control group (p < 0.05). During the whole study, no side effects were observed in both MGD and control groups. Conclusion: MGD was effective in improving disease efficacy, clinical symptoms and reducing time to fever resolution in patients with childhood CAP, which suggested that MGD may be used as an alternative therapy in the treatment of childhood CAP. Clinical Trial Registration: http://www.chictr.org.cn/showproj.aspx?proj=5612, identifier 13003955.
format Online
Article
Text
id pubmed-9479123
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-94791232022-09-17 Efficacy and safety of a Chinese herbal formula Maxing Ganshi Decoction in children with community-acquired pneumonia: A randomized, double-blind, placebo-controlled, multicenter trial Zheng, Yujiao Shi, Changren Han, Yaowei Li, Xinmin Dong, Lijing Li, Yan Chen, Hui Wang, Yushui Li, Jinsong Liu, Geli Ma, Rong Lian, Fengmei Tong, Xiaolin Front Pharmacol Pharmacology Background: As one of the most commonly used Chinese medicine formula in the manage of respiratory diseases, Maxing Ganshi Decoction (MGD) has been demonstrated to improve the clinical symptoms of pneumonia. To evaluate the efficacy and safety of MGD in treating children with community-acquired pneumonia (CAP), we conducted the clinical trial. Methods: A randomized, double-blind, placebo-controlled, multicenter trial was conducted in 3 study sites in Tianjin, China. MDG or placebo were randomly given to patients aged 3–6 years with onset of CAP within 48 h. Changes in disease efficacy during the study period (which was measured as recovery, significant effect, improvement and no effect) was evaluated as the primary outcome. Time from enrollment to fever resolution was assessed as the secondary outcome. The adverse event was analyzed as safety evaluation. Results: A total of 71 patients (36 in MGD and 35 in placebo) were randomized and completed the whole study. The patient demographics and other characteristics at baseline were similar between the 2 groups (p > 0.05). After 10 days of intervention, the proportion of recovered and significant effective patients was increased significantly in the MGD group (34.85% [95% CI, 12.44%–57.26%]; p < 0.05) compared with the control group. Besides, the symptom score of the MGD group was lowered significantly (p < 0.001). The estimated time to fever resolution in the MGD group was also reduced compared with the control group (p < 0.05). During the whole study, no side effects were observed in both MGD and control groups. Conclusion: MGD was effective in improving disease efficacy, clinical symptoms and reducing time to fever resolution in patients with childhood CAP, which suggested that MGD may be used as an alternative therapy in the treatment of childhood CAP. Clinical Trial Registration: http://www.chictr.org.cn/showproj.aspx?proj=5612, identifier 13003955. Frontiers Media S.A. 2022-09-02 /pmc/articles/PMC9479123/ /pubmed/36120338 http://dx.doi.org/10.3389/fphar.2022.948831 Text en Copyright © 2022 Zheng, Shi, Han, Li, Dong, Li, Chen, Wang, Li, Liu, Ma, Lian and Tong. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Zheng, Yujiao
Shi, Changren
Han, Yaowei
Li, Xinmin
Dong, Lijing
Li, Yan
Chen, Hui
Wang, Yushui
Li, Jinsong
Liu, Geli
Ma, Rong
Lian, Fengmei
Tong, Xiaolin
Efficacy and safety of a Chinese herbal formula Maxing Ganshi Decoction in children with community-acquired pneumonia: A randomized, double-blind, placebo-controlled, multicenter trial
title Efficacy and safety of a Chinese herbal formula Maxing Ganshi Decoction in children with community-acquired pneumonia: A randomized, double-blind, placebo-controlled, multicenter trial
title_full Efficacy and safety of a Chinese herbal formula Maxing Ganshi Decoction in children with community-acquired pneumonia: A randomized, double-blind, placebo-controlled, multicenter trial
title_fullStr Efficacy and safety of a Chinese herbal formula Maxing Ganshi Decoction in children with community-acquired pneumonia: A randomized, double-blind, placebo-controlled, multicenter trial
title_full_unstemmed Efficacy and safety of a Chinese herbal formula Maxing Ganshi Decoction in children with community-acquired pneumonia: A randomized, double-blind, placebo-controlled, multicenter trial
title_short Efficacy and safety of a Chinese herbal formula Maxing Ganshi Decoction in children with community-acquired pneumonia: A randomized, double-blind, placebo-controlled, multicenter trial
title_sort efficacy and safety of a chinese herbal formula maxing ganshi decoction in children with community-acquired pneumonia: a randomized, double-blind, placebo-controlled, multicenter trial
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9479123/
https://www.ncbi.nlm.nih.gov/pubmed/36120338
http://dx.doi.org/10.3389/fphar.2022.948831
work_keys_str_mv AT zhengyujiao efficacyandsafetyofachineseherbalformulamaxingganshidecoctioninchildrenwithcommunityacquiredpneumoniaarandomizeddoubleblindplacebocontrolledmulticentertrial
AT shichangren efficacyandsafetyofachineseherbalformulamaxingganshidecoctioninchildrenwithcommunityacquiredpneumoniaarandomizeddoubleblindplacebocontrolledmulticentertrial
AT hanyaowei efficacyandsafetyofachineseherbalformulamaxingganshidecoctioninchildrenwithcommunityacquiredpneumoniaarandomizeddoubleblindplacebocontrolledmulticentertrial
AT lixinmin efficacyandsafetyofachineseherbalformulamaxingganshidecoctioninchildrenwithcommunityacquiredpneumoniaarandomizeddoubleblindplacebocontrolledmulticentertrial
AT donglijing efficacyandsafetyofachineseherbalformulamaxingganshidecoctioninchildrenwithcommunityacquiredpneumoniaarandomizeddoubleblindplacebocontrolledmulticentertrial
AT liyan efficacyandsafetyofachineseherbalformulamaxingganshidecoctioninchildrenwithcommunityacquiredpneumoniaarandomizeddoubleblindplacebocontrolledmulticentertrial
AT chenhui efficacyandsafetyofachineseherbalformulamaxingganshidecoctioninchildrenwithcommunityacquiredpneumoniaarandomizeddoubleblindplacebocontrolledmulticentertrial
AT wangyushui efficacyandsafetyofachineseherbalformulamaxingganshidecoctioninchildrenwithcommunityacquiredpneumoniaarandomizeddoubleblindplacebocontrolledmulticentertrial
AT lijinsong efficacyandsafetyofachineseherbalformulamaxingganshidecoctioninchildrenwithcommunityacquiredpneumoniaarandomizeddoubleblindplacebocontrolledmulticentertrial
AT liugeli efficacyandsafetyofachineseherbalformulamaxingganshidecoctioninchildrenwithcommunityacquiredpneumoniaarandomizeddoubleblindplacebocontrolledmulticentertrial
AT marong efficacyandsafetyofachineseherbalformulamaxingganshidecoctioninchildrenwithcommunityacquiredpneumoniaarandomizeddoubleblindplacebocontrolledmulticentertrial
AT lianfengmei efficacyandsafetyofachineseherbalformulamaxingganshidecoctioninchildrenwithcommunityacquiredpneumoniaarandomizeddoubleblindplacebocontrolledmulticentertrial
AT tongxiaolin efficacyandsafetyofachineseherbalformulamaxingganshidecoctioninchildrenwithcommunityacquiredpneumoniaarandomizeddoubleblindplacebocontrolledmulticentertrial